BREAST RADIOLOGY / REVIEW PAPER
The role of magnetic resonance imaging (MRI) in breast cancer molecular subtypes
1
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Submission date: 2025-03-22
Final revision date: 2025-04-24
Acceptance date: 2026-01-06
Publication date: 2026-07-01
Corresponding author
Guanwu Li
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No. 110 Ganhe Road, Hongkou District, Shanghai 200437, China
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No. 110 Ganhe Road, Hongkou District, Shanghai 200437, China
Pol J Radiol, 2026; 91(1): 288-298
KEYWORDS
TOPICS
ABSTRACT
Breast cancer heterogeneity is crucial for treatment decision-making and prognosis prediction. Magnetic resonance imaging (MRI) is a key tool in breast imaging, providing a non-invasive assessment of morphological characteristics, cell density, hemodynamics, and vascular proliferation. Integrating MRI with advanced techniques such as radiomics, habitat imaging, and artificial intelligence enables a deeper understanding of tumor morphology and biological behavior through analysis of imaging features, thereby characterizing the heterogeneity inherent in breast cancer. This review explores MRI’s role as an imaging biomarker for evaluating breast cancer molecular subtypes, aiming to support personalized treatment strategies and improve therapeutic outcomes.
REFERENCES (102)
1.
Lüönd F, Tiede S, Christofori G. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer 2021; 125: 164-175.
2.
Xiao J, Rahbar H, Hippe DS, Rendi MH, Parker EU, Shekar N, et al. Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis. NPJ Breast Cancer 2021; 7: 42. DOI: 10.1038/s41523-021-00247-3.
3.
Ao F, Yan Y, Zhang ZL, Li S, Li WJ, Chen GB. The value of dynamic contrast-enhanced magnetic resonance imaging combined with apparent diffusion coefficient in the differentiation of benign and malignant diseases of the breast. Acta Radiol 2021; 63: 891-900.
4.
Mayerhoefer ME, Materka A, Langs G, Häggström I, Szczypiński P, Gibbs P, Cook G. Introduction to radiomics. J Nucl Med 2020; 61: 488-495.
5.
Guo Y, Kong QC, Li LQ, Tang WJ, Zhang WL, Ning GY, et al. Whole volume apparent diffusion coefficient (ADC) histogram as a quantitative imaging biomarker to differentiate breast lesions: correlation with the Ki-67 proliferation index. Biomed Res Int 2021; 2021: 4970265. DOI: 10.1155/2021/4970265.
6.
Parekh VS, Jacobs MA. Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging. Breast Cancer Res Treat 2020; 180: 407-421.
7.
Fan W, Sun W, Xu MZ, Pan JJ, Man FY. Diagnosis of benign and malignant nodules with a radiomics model integrating features from nodules and mammary regions on DCE-MRI. Front Oncol 2024; 14: 1307907. DOI: 10.3389/fonc.2024.1307907.
8.
Kim JY, Kim JJ, Hwangbo L, Lee JW, Lee NK, Nam KJ, et al. Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk. Eur Radiol 2020; 30: 66-76.
9.
Tar PD, Thacker NA, Babur M, Lipowska-Bhalla G, Cheung S, Little RA, et al. Habitat imaging of tumors enables high confidence sub-regional assessment of response to therapy. Cancers (Basel) 2022; 14: 2159. DOI: 10.3390/cancers14092159.
10.
Kazerouni AS, Hormuth DA 2nd, Davis T, Bloom MJ, Mounho S, Rahman G, et al. Quantifying tumor heterogeneity via MRI habitats to characterize microenvironmental alterations in HER2+ breast cancer. Cancers (Basel) 2022; 14: 1837. DOI: 10.3390/cancers-14071837.
11.
Jeibouei S, Akbari M E, Kalbasi A, Aref AR, Ajoudanian M, Rezvani A, Zali H. Personalized medicine in breast cancer: pharmacogenomics approaches. Pharmacogenomics Pers Med 2019; 12: 59-73.
12.
Ramón Y Cajal S, Sesé M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl) 2020; 98: 161-177.
13.
Vitale I, Shema E, Loi S, Galluzzi L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med 2021; 27: 212-224.
14.
Tendl KA, Bago-Horvath Z. Molecular profiling in breast cancer – ready for clinical routine? memo – Magazine of European Medical Oncology 2020; 13: 445-449.
15.
Hasan AM, Al-Waely NKN, Aljobouri HK, Jalab HA, Ibrahim RW, Meziane F. Molecular subtypes classification of breast cancer in DCE-MRI using deep features. Expert Systems with Applications 2024, 236: 121371. DOI: https://doi.org/10.1016/j.eswa....
16.
Adani-Ifè A, Amégbor K, Doh K, Darré T. Breast cancer in togolese women: immunohistochemistry subtypes. BMC Womens Health 2020; 20: 261. DOI: 10.1186/s12905-020-01130-2.
17.
Stevanovic L, Choschzick M, Moskovszky L, Varga Z. Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018. J Cancer Res Clin Oncol 2019; 145: 2983-2994.
18.
He X, Wang Z, Zhou Y, Feng Y. The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer. Front Oncol 2023; 13: 1132186. DOI: 10.3389/fonc.2023.1132186.
19.
Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007; 74: 72-84.
20.
Leithner D, Wengert GJ, Helbich TH, Thakur S, Ochoa-Albiztegui RE, Morris EA, Pinker K. Clinical role of breast MRI now and going forward. Clin Radiol 2018; 73: 700-714.
21.
Xue F, Meng Y, Jiang J. Diagnostic value of dynamic enhanced magnetic resonance imaging combined with serum CA15-3, CYFRA21-1, and TFF1 for breast cancer. J Healthc Eng 2022; 2022: 7984591. DOI: 10.1155/2022/7984591.
22.
Karavas E, Ece B, Aydın S. Type 2 dynamic curves: a diagnostic dilemma. World J Radiol 2022; 14: 229-237.
23.
Galati F, Rizzo V, Trimboli RM, Kripa E, Maroncelli R, Pediconi F. MRI as a biomarker for breast cancer diagnosis and prognosis. BJR Open 2022; 4: 20220002. DOI: 10.1259/bjro.20220002.
24.
Seyfettin A, Dede I, Hakverdi S, Düzel Asıg B, Temiz M, Karazincir S. MR imaging properties of breast cancer molecular subtypes. Eur Rev Med Pharmacol Sci 2022; 26: 3840-3848.
25.
Pinker K, Shitano F, Sala E, Do RK, Young RJ, Wibmer AG, et al. Background, current role, and potential applications of radiogenomics. J Magn Reson Imaging 2017; 47: 604-620.
26.
Bergholtz H, Lien TG, Swanson DM, Frigessi A; Oslo Breast Cancer Research Consortium (OSBREAC); Daidone MG, Tost J, Wärnberg F, Sørlie T. Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions. NPJ Breast Cancer 2020; 6: 26. DOI: 10.1038/s41523-020-0167-x.
27.
Tuan Linh L, Minh Duc N, Tra My TT, Viet Bang L, Minh Pham T. Correlations between dynamic contrast-enhanced magnetic resonance imaging parameters and histopathologic factors in breast cancer. Clin Ter 2021; 172: 453-460.
28.
Moffa G, Galati F, Collalunga E, Rizzo V, Kripa E, D’Amati G, Pediconi F. Can MRI biomarkers predict triple-negative breast cancer? Diagnostics (Basel) 2020; 10: 1090. DOI: 10.3390/diagnostics-10121090.
29.
Du S, Gao S, Zhang L, Yang X, Qi X, Li S. Improved discrimination of molecular subtypes in invasive breast cancer: comparison of multiple quantitative parameters from breast MRI. Magn Reson Imaging 2021; 77: 148-158.
30.
Huang Y, Zheng C, Zhang X, Cheng Z, Yang Z, Hao Y, Shen J. The usefulness of bayesian network in assessing the risk of triple-negative breast cancer. Acad Radiol 2020; 27: e282-e291. DOI: https://doi.org/10.1016/j.acra....
31.
Lai T, Chen X, Yang Z, Huang R, Liao Y, Chen X, Dai Z. Quantitative parameters of dynamic contrast-enhanced magnetic resonance imaging to predict lymphovascular invasion and survival outcome in breast cancer. Cancer Imaging 2022; 22: 61. DOI: 10.1186/s40644-022-00499-7.
32.
Kazama T, Takahara T, Hashimoto J. Breast cancer subtypes and quantitative magnetic resonance imaging: a systemic review. Life (Basel) 2022; 12: 490. DOI: 10.3390/life12040490.
33.
Shao Y, Bao X, Song C, Cui D. Application of dynamic enhanced magnetic resonance imaging in the diagnosis of hematological malignancies. J Healthc Eng 2021; 2021: 4623850. DOI: 10.1155/2021/4623850.
34.
Li X, Fu P, Jiang M, Zhang J, Tan L, Ai T, Li X. The diagnostic performance of dynamic contrast-enhanced MRI and its correlation with subtypes of breast cancerJ]. Medicine (Baltimore) 2021; 100: e28109. DOI: 10.1097/MD.0000000000028109.
35.
Cheng X, Chen C, Xia H, Zhang L, Xu M. 3.0 T magnetic resonance functional imaging quantitative parameters for differential diagnosis of benign and lesions of the breast. Cancer Biother Radiopharm 2021; 36: 448-455.
36.
Setiawan K, Suryawisesa IB, Widiana IK, Sudarsa IW. Does a 40% cut-off point for ki-67 expression have a role in identifying the development of distant metastasis within 2 years in locally advanced triple negative breast cancer patients? Eur J Breast Health 2023; 19: 274-278.
37.
Li A, Pan Y, Chen B, Huang R, Xia J, Jin Y, Zheng J. Evaluation of quantitative dynamic contrast-enhanced (DCE)-MRI parameters using a reference region model in invasive ductal carcinoma (IDC) patients. Int J Imaging Syst Technol 2021; 31: 215-222.
38.
Tezcan S, Ozturk FU, Uslu N, Akcay EY. The role of combined diffusion-weighted imaging and dynamic contrast-enhanced MRI for differentiating malignant from benign breast lesions presenting washout curve. Can Assoc Radiol J 2021; 72: 460-469.
39.
Ulas C, Das D, Thrippleton MJ, Valdés Hernández MDC, Armitage PA, Makin SD, et al. Convolutional neural networks for direct inference of pharmacokinetic parameters: application to stroke dynamic contrast-enhanced MRI. Front Neurol 2019, 9: 1147. DOI: 10.3389/fneur.2018.01147.
40.
Kataoka M, Honda M, Ohashi A, Yamaguchi K, Mori N, Goto M, et al. Ultrafast dynamic contrast-enhanced MRI of the breast: how is it used? Magn Reson Med Sci 2022; 21: 83-94.
41.
Honda M, Kataoka M, Iima M, Miyake KK, Ohashi A, Kishimoto AO, et al. Background parenchymal enhancement and its effect on lesion detectability in ultrafast dynamic contrast-enhanced MRI. Eur J Radiol 2020; 129: 108984. DOI: 10.1016/j.ejrad.2020.108984.
42.
Honda M, Kataoka M, Onishi N, Iima M, Ohashi A, Kanao S, et al. New parameters of ultrafast dynamic contrast-enhanced breast MRI using compressed sensing. J Magn Reson Imaging 2019; 51: 164-174.
43.
Onishi N, Sadinski M, Gibbs P, Gallagher KM, Hughes MC, Ko ES, et al. Differentiation between subcentimeter carcinomas and benign lesions using kinetic parameters derived from ultrafast dynamic contrast-enhanced breast MRI. Eur Radiol 2019; 30: 756-766.
44.
Onishi N, Sadinski M, Hughes MC, Ko ES, Gibbs P, Gallagher KM, et al. Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer. Breast Cancer Res 2020; 22: 58. DOI: 10.1186/s13058-020-01292-9.
45.
Goto M, Sakai K, Yokota H, Kiba M, Yoshida M, Imai H, et al. Diagnostic performance of initial enhancement analysis using ultra-fast dynamic contrast-enhanced MRI for breast lesions. Eur Radiol 2018; 29: 1164-1174.
46.
Yamaguchi K, Nakazono T, Egashira R, Fukui S, Baba K, Hamamoto T, Irie H. Maximum slope of ultrafast dynamic contrast-enhanced MRI of the breast: comparisons with prognostic factors of breast cancer. Jpn J Radiol 2020; 39: 246-253.
47.
Zhang M, Horvat J V, Bernard-Davila B, Marino MA, Leithner D, Ochoa-Albiztegui RE, et al. Multiparametric MRI model with dynamic contrast-enhanced and diffusion-weighted imaging enables breast cancer diagnosis with high accuracy. J Magn Reson Imaging 2019; 49: 864-874.
48.
Maric J, Boban J, Ivkovic-Kapicl T, Djilas D, Vucaj-Cirilovic V, Bogdanovic-Stojanovic D. Differentiation of breast lesions and distinguishing their histological subtypes using diffusion-weighted imaging and ADC values. Front Oncol 2020; 10: 332. DOI: 10.3389/fonc.2020.00332.
49.
Goto M, Le Bihan D, Sakai K, Yamada K. The diffusion MRI signature index is highly correlated with immunohistochemical status and molecular subtype of invasive breast carcinoma. Eur Radiol 2022; 32: 4879-4888.
50.
Rupa R, Thushara R, Swathigha S, Athira R, Meena N, Cherian MP. Diffusion weighted imaging in breast cancer – can it be a noninvasive predictor of nuclear grade? Indian J Radiol Imaging 2020; 30: 13-19.
51.
Meyer H J, Wienke A, Surov A. Diffusion-weighted imaging of different breast cancer molecular subtypes: a systematic review and meta-analysis. Breast Care (Basel) 2022; 17: 47-54.
52.
Billy CA, Darmiati S, Prihartono J. Diagnostic accuracy of diffusion weighted imaging compared to magnetic resonance spectroscopy in differentiation of benign and malignant breast lesions: a systematic review and meta-analysis. Eur J Radiol 2023; 168: 111124. DOI: 10.1016/j.ejrad.2023.111124.
53.
Messina C, Bignone R, Bruno A, Bruno A, Bruno F, Calandri M, et al. Diffusion-weighted imaging in oncology: an update. Cancers (Basel) 2020; 12: 1493. DOI: 10.3390/cancers12061493.
54.
Horvat JV, Bernard-Davila B, Helbich TH, Zhang M, Morris EA, Thakur SB, et al. Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer. J Magn Reson Imaging 2019; 50: 836-846.
55.
Wang Y, Jin Y, Li M, Zhang J, Wang S, Zhang H, Song B, et al. Diagnostic performance of mono-exponential DWI versus diffusion kurtosis imaging in breast lesions: a meta-analysis. Medicine (Baltimore) 2022; 101: e31574. DOI: 10.1097/MD.0000000000031574.
56.
Yao FF, Zhang Y. A review of quantitative diffusion-weighted MR imaging for breast cancer: towards noninvasive biomarker. Clin Imaging 2023; 98: 36-58.
57.
Qin Y, Wu F, Hu Q, He L, Huo M, Tang C, et al. Histogram analysis of multi-model high-resolution diffusion-weighted MRI in breast cancer: correlations with molecular prognostic factors and subtypes. Front Oncol 2023; 13: 1139189. DOI: 10.3389/fonc.2023.1139189.
58.
Liang J, Zeng S, Li Z, Kong Y, Meng T, Zhou C, et al. Intravoxel incoherent motion diffusion-weighted imaging for quantitative differentiation of breast tumors: a meta-analysis. Front Oncol 2020; 10: 585486. DOI: 10.3389/fonc.2020.585486.
59.
Meng N, Wang X J, Sun J, Huang L, Wang Z, Wang KY, et al. Comparative study of amide proton transfer-weighted imaging and intravoxel incoherent motion imaging in breast cancer diagnosis and evaluation. J Magn Reson Imaging 2020; 52: 1175-1186.
60.
Uslu H, Önal T, Tosun M, Arslan AS, Ciftci E, Utkan NZ. Intravoxel incoherent motion magnetic resonance imaging for breast cancer: a comparison with molecular subtypes and histological grades. Magn Reson Imaging 2021; 78: 35-41.
61.
Ma Y, Shan D, Wei J, Chen A. Application of intravoxel incoherent motion diffusion-weighted imaging in differential diagnosis and molecular subtype analysis of breast cancer. Am J Transl Res 2021; 13: 3034-3043.
62.
Honda M, Le Bihan D, Kataoka M, Iima M. Diffusion kurtosis imaging as a biomarker of breast cancer. BJR Open 2023; 5: 20220038. DOI: 10.1259/bjro.20220038.
63.
Zhang J, Chen Y, Zhang E, Li N, Yuan H, Lang N. Use of monoexponential diffusion-weighted imaging and diffusion kurtosis imaging and dynamic contrast-enhanced-MRI for the differentiation of spinal tumors. Eur Spine J 2020; 29: 1112-1120.
64.
Zhang J, Xing X, Wang Q, Chen Y, Yuan H, Lang N. Preliminary study of monoexponential, biexponential, and stretched-exponential models of diffusion-weighted MRI and diffusion kurtosis imaging on differential diagnosis of spinal metastases and chordoma. Eur Spine J 2022; 31: 3130-3138.
65.
Zhou WP, Zan XY, Hu XY, Liu X, Sudarshan SKP, Yang SD, et al. Characterization of breast lesions using diffusion kurtosis model-based imaging: an initial experience. J Xray Sci Technol 2020; 28: 157-169.
66.
Yang ZL, Li Y, Zhan CA, Hu YQ, Guo YH, Xia LM, Ai T. Evaluation of suspicious breast lesions with diffusion kurtosis MR imaging and connection with prognostic factors. Eur J Radiol 2021; 145: 110014. DOI: 10.1016/j.ejrad.2021.110014.
67.
Meng N, Wang X, Sun J, Han D, Bai Y, Wei W, et al. A comparative study of the value of amide proton transfer-weighted imaging and diffusion kurtosis imaging in the diagnosis and evaluation of breast cancer. Eur Radiol 2020; 31: 1707-1717.
68.
Huang Y, Lin Y, Hu W, Ma C, Lin W, Wang Z, et al. Diffusion curtosis at 3.0T as an in vivo imaging marker for breast cancer characterization: correlation with prognostic factors. J Magn Reson Imaging 2019; 49: 845-856.
69.
Kang HS, Kim JY, Kim JJ, Kim S, Lee NK, Lee JW, et al. Diffusion kurtosis MR imaging of invasive breast cancer: correlations with prognostic factors and molecular subtypes. J Magn Reson Imaging 2022; 56: 110-120.
70.
You C, Li J, Zhi W, Chen Y, Yang W, Gu Y, Peng W, et al. The volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI: association with prognostic factors in HER2-positive breast cancer. J Transl Med 2019; 17: 182. DOI: 10.1186/s12967-019-1911-6.
71.
Li X, Fan Z, Jiang H, Niu J, Bian W, Wang C, et al. Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression status. Sci Rep 2023; 13: 17978. DOI: 10.1038/s41598-023-45079-2.
72.
Gao W, Zhang S, Guo J, Wei X, Li X, Diao Y, et al. Investigation of synthetic relaxometry and diffusion measures in the differentiation of benign and malignant breast lesions as compared to BI-RADS. J Magn Reson Imaging 2020; 53: 1118-1127.
73.
Matsuda M, Tsuda T, Ebihara R, Toshimori W, Takeda S, Okada K, et al. Enhanced masses on contrast-enhanced breast: differentiation using a combination of dynamic contrast-enhanced MRI and quantitative evaluation with synthetic MRI. J Magn Reson Imaging 2020; 53: 381-391.
74.
Sun SY, Ding Y, Li Z, Nie L, Liao C, Liu Y, et al. Multiparameter MRI model with DCE-MRI, DWI, and synthetic MRI improves the diagnostic performance of BI-RADS 4 lesions. Front Oncol 2021; 11: 699127. DOI: 10.3389/fonc.2021.699127.
75.
Li Q, Xiao Q, Yang M, Chai Q, Huang Y, Wu PY, et al. Histogram analysis of quantitative parameters from synthetic MRI: correlations with prognostic factors and molecular subtypes in invasive ductal breast cancer. Eur J Radiol 2021; 139: 109697. DOI: 10.1016/j.ejrad.2021.109697.
76.
Gao W, Yang Q, Li X, Chen X, Wei X, Diao Y, et al. Synthetic MRI with quantitative mappings for identifying receptor status, proliferation rate, and molecular subtypes of breast cancer. Eur J Radiol 2022; 148: 110168. DOI: 10.1016/j.ejrad.2022.110168.
77.
Yuen S, Monzawa S, Yanai S, Matsumoto H, Yata Y, Ichinose Y, et al. The association between MRI findings and breast cancer subtypes: focused on the combination patterns on diffusion-weighted and T2-weighted images. Breast Cancer 2020; 27: 1029-1037.
78.
79 Zhang Q, Zhao Y, Nie J, Long Q, Wang X, Wang X, et al. Pretreatment synthetic MRI features for triple-negative breast cancer. Clin Radiol 2023; 79: e219-e226. DOI: 10.1016/j.crad.2023.10.015.
79.
Tomaszewski MR, Gillies RJ. The biological meaning of radiomic features. Radiology 2021; 298: 505-516.
80.
Lafcı O, Celepli P, Seher Öztekin P, Koşar PN. DCE-MRI radiomics analysis in differentiating luminal A and luminal B breast cancer molecular subtypes. Acad Radiol 2022; 30: 22-29.
81.
Slavkova KP, Patel SH, Cacini Z, Kazerouni AS, Gardner AL, Yankeelov TE, Hormuth DA 2nd. Mathematical modelling of the dynamics of image-informed tumor habitats in a murine model of glioma. Sci Rep 2023; 13: 2916. DOI: 10.1038/s41598-023-30010-6.
82.
Xie T, Zhao Q, Fu C, Bai Q, Zhou X, Li L, et al. Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on multiparametric MR imaging. Eur Radiol 2019; 29: 2535-2544.
83.
Corrias G, Micheletti G, Barberini L, Suri JS, Saba L. Texture analysis imaging “what a clinical radiologist needs to know”. Eur J Radiol 2022; 146: 110055. DOI: https://doi.org/10.1016/j.ejra....
84.
van Timmeren JE, Cester D, Tanadini-Lang S, Alkadhi H, Baessler B. Radiomics in medical imaging – ”how-to” guide and critical reflection. Insights Imaging 2020; 11: 91. DOI: 10.1186/s13244-020-00887-2.
85.
Du T, Zhao H. Habitat analysis of breast cancer-enhanced MRI reflects BRCA1 mutation determined by immunohistochemistry. Biomed Res Int 2022; 2022: 9623173. DOI: 10.1155/2022/9623173.
86.
Leithner D, Horvat JV, Marino MA, Bernard-Davila B, Jochelson MS, Ochoa-Albiztegui RE, et al. Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results. Breast Cancer Res 2019; 21: 106. DOI: 10.1186/s13058-019-1187-z.
87.
Leithner D, Bernard-Davila B, Martinez DF, Horvat JV, Jochelson MS, Marino MA, et al. Radiomic signatures derived from diffusion-weighted imaging for the assessment of breast cancer receptor status and molecular subtypes. Mol Imaging Biol 2020; 22: 453-461.
88.
Horvat JV, Iyer A, Morris EA, Apte A, Bernard-Davila B, Martinez DF, et al. Histogram analysis and visual heterogeneity of diffusion-weighted imaging with apparent diffusion coefficient mapping in the prediction of molecular subtypes of invasive breast cancers. Contrast Media Mol Imaging 2019; 2019: 2972189. DOI: 10.1155/2019/2972189.
89.
Chang Y C, Ackerstaff E, Tschudi Y, Jimenez B, Foltz W, Fisher C, et al. Delineation of tumor habitats based on dynamic contrast enhanced MRI. Sci Rep 2017; 7: 9746. DOI: 10.1038/s41598-017-09932-5.
90.
Gillies RJ, Balagurunathan Y. Perfusion MR imaging of breast cancer: insights using “habitat imaging”. Radiology 2018; 288: 36-37.
91.
Kim JJ, Kim JY, Suh HB, Hwangbo L, Lee NK, Kim S, et al. Characterization of breast cancer subtypes based on quantitative assessment of intratumoral heterogeneity using dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging. Eur Radiol 2022; 32: 822-833.
92.
Kim M, Park JE, Kim HS, Kim N, Park SY, Kim YH, Kim JH, et al. Spatiotemporal habitats from multiparametric physiologic MRI distinguish tumor progression from treatment-related change in post-treatment glioblastoma. Eur Radiol 2021; 31: 6374-6383.
93.
Cho HH, Kim H, Nam SY, Lee JE, Han BK, Ko EY, et al. Measurement of perfusion heterogeneity within tumor habitats on magnetic resonance imaging and its association with prognosis in breast cancer patients. Cancers (Basel) 2022; 14: 1858. DOI: 10.3390/cancers14081858.
94.
Zhang L, Fan M, Wang S, Xu M, Li L. Radiomic analysis of pharmacokinetic heterogeneity within tumor based on the unsupervised decomposition of dynamic contrast-enhanced MRI for predicting histological characteristics of breast cancer. J Magn Reson Imaging 2022; 55: 1636-1647.
95.
Wang H, Zeng L, Wu H, Tian J, Xie H, Zhang L, et al. Preoperative vascular heterogeneity based on dynamic susceptibility contrast MRI in predicting spatial pattern of locally recurrent high-grade gliomas. Eur Radiol 2024; 34: 1982-1993.
96.
Feng S, Yin J. Dynamic contrast-enhanced magnetic resonance imaging radiomics analysis based on intratumoral subregions for predicting luminal and nonluminal breast cancer. Quant Imaging Med Surg 2023; 13: 6735-6749.
97.
Lu H, Yin J. Texture analysis of breast DCE-MRI based on intratumoral subregions for predicting HER2 2+ status. Front Oncol 2020; 10: 543. DOI: 10.3389/fonc.2020.00543.
98.
Xu R, Yu D, Luo P, Li X, Jiang L, Chang S, Li G. Do habitat MRI and fractal analysis help distinguish triple-negative breast cancer from non-triple-negative breast carcinoma. Can Assoc Radiol J 2024; 75: 584-592.
99.
Ren W, Xi X, Zhang X, Wang K, Liu M, Wang D, et al. Predicting molecular subtypes of breast cancer based on multi-parametric MRI dataset using deep learning method. Magn Reson Imaging 2024; 117: 110305. DOI: 10.1016/j.mri.2024.110305.
100.
Wang X, Hu X, Wang C, Yang H, Hu Y, Lan X, et al. Automatic segmentation and molecular subtype classification of breast cancer using an MRI-based deep learning framework. Radiol Imaging Cancer 2025; 7: e240184. DOI: 10.1148/rycan.240184.
101.
Ba ZC, Zhang HX, Liu AY, Zhou XX, Liu L, Wang XY, et al. Combination of DCE-MRI and NME-DWI via deep neural network for predicting breast cancer molecular subtypes. Clin Breast Cancer 2024; 24: e417-e427. DOI: 10.1016/j.clbc.2024.03.006.
102.
Huang G, Du S, Gao S, Guo L, Zhao R, Bian X, et al. Molecular subtypes of breast cancer identified by dynamically enhanced MRI radiomics: the delayed phase cannot be ignored. Insights Imaging 2024; 15: 127. DOI: 10.1186/s13244-024-01713-9.
Share
RELATED ARTICLE
| ISSN: | 1899-0967 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
